ArticleInternational journal of general medicine2025
The Prognostic Significance of TMSB4X in Glioma Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The implications of TMSB4X in TIM3 hypermethylation and CD8Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The goal of this study was to analyze in depth the importance of the thymosin beta 4 X-linked gene (TMSB4X) in the disease process of gliomas for the prediction of patient prognosis. Methods: We explored the expression of TMSB4X by analyzing datasets from The Cancer Genome Atlas (TCGA) datasets and the Chinese Glioma Genome Atlas (CGGA). Tumor sample tissues and corresponding paracancerous tissues of glioma patients were collected, and TMSB4X expression in glioma tissues was analyzed using Real-Time PCR to investigate its prognostic significance in glioma patients. In addition, we have plotted the ROC curves for the survival rate, performed univariate and multivariate Cox analyses and constructed nomogram. Differential expression analyses were performed on the basis of median expression levels of the TMSB4X gene, and Intuitive graphical presentation and visualisation of the 403 proteins screened were carried out using the Cytoscape software platform. (version: 3.9.1). The top 50 core genes were then screened using the cyto Hubba algorithm, these genes were analyzed using The Gene Ontology Database (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). TCGA datasets was utilized for Gene Set Enrichment Analysis (GSEA) to obtain potential NF-κB-related pathways in gliomas. Results: Independent prognostic analyses show that the TMSB4X gene was identified as an independent prognostic indicator for gliomas. In GOKEGG and GSEA analyses, the analyses indicate that TMSB4X may play a crucial role in glioma patients by up-regulating I-kappaB kinase/NF-kappaB signaling. In glioma patients, upregulation of the I-kappaB kinase and NF-kappaB signalling pathways plays a crucial role, which may be linked to CASP1. Conclusion: The findings showed that TMSB4X was identified as an potential independent risk factor in the prognosis of glioma patients, a finding that implies that TMSB4X has the potential to serve as a key biomarker for predicting the prognostic status of glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.